Soyugelen Demirok Gülizar, Ekşioğlu Ümit, Yakın Mehmet, Kaderli Ahmet, Kaderli Sema Tamer, Örnek Firdevs
Ankara Training and Research Hospital, Ophthalmology Clinic, Ankara, Turkey
Turk J Ophthalmol. 2019 Sep 3;49(4):183-187. doi: 10.4274/tjo.galenos.2019.07348.
To report the results obtained from glaucoma drainage device (GDD) implantation in patients with aniridia-related glaucoma and to review the literature.
We retrospectively reviewed 6 patients who underwent GDD implantation for glaucoma secondary to congenital aniridia between April 2001 and February 2015. Data on age at surgery, gender, laterality, surgeries before GDD implantation, GDD model, concomitant ocular disorders, visual acuity, and intraocular pressure (IOP) values before and at 1 and 12 months after GDD implantation, medications, follow-up period, findings during last visit, complications, and course of disease were collected.
Mean age at surgery was 16.00±12.31 years (range 5-37 years). Mean IOP was 33.00±12.11 (range 22-50) mmHg just before the GDD implantation with a mean of 3.5±1.2 medications. Mean IOP 1 month after implantation was 16.33±4.22 (range 12-24) mmHg with a mean of 1.5±0.8 medications; at 12 months, mean IOP was 19.50±4.76 (range 15-26) mmHg with 3.0±0.8 medications. At the last follow-up visit, IOP was 21.16±4.07 (range 16-26) mmHg with a mean of 3.33±0.51 medications. Mean follow-up was 19.16±8.8 (range 12-36) months. Surgical success rates were 83.3%, 66.6%, and 50.0% at 1 month, 12 months, and the last visit, respectively.
GDD implantation was effective in controlling aniridic glaucoma with a success rate of 83.3% at 1-month follow-up and 66.6% at 1-year follow-up. Therefore, it should be considered as an initial surgical treatment for aniridic glaucoma; the clinician should be alert for concomitant ocular disorders.
报告在无虹膜相关性青光眼患者中植入青光眼引流装置(GDD)所获得的结果并复习相关文献。
我们回顾性分析了2001年4月至2015年2月期间因先天性无虹膜继发青光眼而接受GDD植入术的6例患者。收集了手术时年龄、性别、患侧、GDD植入术前的手术情况、GDD型号、合并的眼部疾病、视力、GDD植入术前、术后1个月和12个月时的眼压(IOP)值、用药情况、随访时间、末次随访时的检查结果、并发症及疾病进程等数据。
手术时的平均年龄为16.00±12.31岁(范围5 - 37岁)。在GDD植入术前,平均眼压为33.00±12.11(范围22 - 50)mmHg,平均用药3.5±1.2种。植入术后1个月,平均眼压为16.33±4.22(范围12 - 24)mmHg,平均用药1.5±0.8种;术后12个月,平均眼压为19.50±4.76(范围15 - 26)mmHg,用药3.0±0.8种。在末次随访时,眼压为21.16±4.07(范围16 - 26)mmHg,平均用药3.33±0.51种。平均随访时间为19.16±8.8(范围12 - 36)个月。术后1个月、术后12个月及末次随访时的手术成功率分别为83.3%、66.6%和50.0%。
GDD植入术在控制无虹膜性青光眼方面有效,随访1个月时成功率为83.3%,随访1年时成功率为66.6%。因此,应将其视为无虹膜性青光眼的初始手术治疗方法;临床医生应警惕合并的眼部疾病。